Antegrin Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Merger of Eq.

Antegrin Therapeutics General Information

Description

Developer of compounds to treat lung disease. The company is developing compounds for the treatment of human fibrotic disease, initially targeting idiopathic pulmonary fibrosis, a progressive life-threatening condition.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare
Primary Office
  • 4320 Forest Park Avenue
  • Suite 304
  • Saint Louis, MO 63108
  • United States
+1 (314) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antegrin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger of Equals 17-Oct-2016 00000 Completed Startup
2. Early Stage VC 02-Oct-2015 00000 00000 Completed Pre-Clinical Trials
1. Early Stage VC 02-Apr-2013 Completed Startup
To view Antegrin Therapeutics’s complete valuation and funding history, request access »

Antegrin Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
George Capps II Director, Business Development
Robert Karr MD President, Chief Executive Officer & Board Member
Peter Ruminski Co-Founder & Scientific Advisor
Rajesh Devraj Ph.D Chairman
To view Antegrin Therapeutics’s complete executive team members history, request access »

Antegrin Therapeutics Board Members (6)

Name Representing Role Since
David Griggs Ph.D Indalo Therapeutics Co-Founder & Board Member 000 0000
Michael Yeadon Ph.D Self Board Member 000 0000
Rajesh Devraj Ph.D Self Chairman 000 0000
Robert Karr MD Self President, Chief Executive Officer & Board Member 000 0000
Thomas Cirrito Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Antegrin Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioGenerator Venture Capital Minority 000 0000 000000 0
Missouri Technology Corporation Venture Capital Minority 000 0000 000000 0
iSelect Fund Venture Capital Minority 000 0000 000000 0
To view Antegrin Therapeutics’s complete investors history, request access »